MergerLinks - Request Credit - Hikma Pharmaceuticals completed the acquisition of the US finished dosage form business of Xellia Pharmaceuticals for $185m.

Submit Deal

Request Deal Involvement

Hikma Pharmaceuticals completed the acquisition of the US finished dosage form business of Xellia Pharmaceuticals for $185m.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

pr advisors

Teneo

legal advisors

Wolf Theiss

Principals

bidder

HIKMA PHARMACEUTICALS INC

target

XELLIA PHARMACEUTICALS (US FINISHED DOSAGE FORM BUSINESS)

vendor

XELLIA PHARMACEUTICALS

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.

To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal: